REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

Data ReadoutRGX-202Neutral

AI Analysis

Summary

REGENXBIO will host a webcast on May 14, 2026 to discuss topline results from a pivotal trial of RGX-202 for Duchenne Muscular Dystrophy, along with first quarter 2026 financial results.

Clinical Trial Data

Phase

Phase_3

Outcome Details

Topline results from pivotal trial

Importance:7/10

Sentiment:

0.00

rare diseasegene therapymuscular dystrophypivotal trialtopline results

Related Companies

$RGNX

Read the original article

Published by PR Newswire Biotech on May 6, 2026 11:05 AM

Read Original